Bionano Genomics (BNGO) Other Non-Current Liabilities (2017 - 2024)

Bionano Genomics (BNGO) has 8 years of Other Non-Current Liabilities data on file, last reported at $5.8 million in Q2 2024.

• For the quarter ending Q2 2024, Other Non-Current Liabilities fell 60.37% year-over-year to $5.8 million; the trailing twelve-month figure through Jun 2024 stood at $5.8 million (down 60.37% YoY), and the FY2023 full-year result was $10.9 million, down 16.04% from the prior year.
• Other Non-Current Liabilities declined to $5.8 million in Q2 2024, from $10.2 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $14.9 million in Q3 2023 to a low of $75000.0 in Q3 2020.
• A 5-year average of $9.2 million and a median of $10.6 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities surged 209.33% in 2021 and slumped 60.37% in 2024, its largest moves.
• Tracing BNGO's Other Non-Current Liabilities over 5 years: stood at $75000.0 in 2020, then surged by 11988.0% to $9.1 million in 2021, then jumped by 43.06% to $13.0 million in 2022, then dropped by 16.04% to $10.9 million in 2023, then tumbled by 46.98% to $5.8 million in 2024.
• Business Quant data shows BNGO's Other Non-Current Liabilities at $5.8 million in Q2 2024, $10.2 million in Q1 2024, and $10.9 million in Q4 2023.